Mayzent
Scottish Medicines Consortium gives go-ahead for Novartis’ Mayzent in secondary progressive multiple sclerosis
October 15, 2020Sales and Marketing Mayzent, Novartis, Scotland
Novartis’ Mayzent (siponimod) has been approved by the Scottish Medicines Consortium in the treatment of secondary progressive multiple sclerosis (SPMS) …
NICE knocks back Novartis’ Mayzent in secondary progressive multiple sclerosis over data gaps
June 25, 2020Sales and Marketing Mayzent, NHS, NICE, Novartis
Novartis’ Mayzent (siponimod) has been unsuccessful in securing a recommendation from NICE for use on the NHS for the treatment …
Five-year data supports early treatment with Novartis’ Mayzent in secondary progressive multiple sclerosis
April 21, 2020Manufacturing and Production, Research and Development Mayzent, Novartis, pharma
Novartis has pulled back the curtain on five-year data from an extension trial for its sphingosine 1-phosphate receptor modulator Mayzent …
EMA advisory panel recommends Mayzent for secondary progressive multiple sclerosis
November 18, 2019Sales and Marketing Europe, Mayzent, Novartis, multiple sclerosis, pharma
Novartis has revealed that Mayzent (siponimod) has been recommended by the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
Novartis’ Mayzent delays time wheelchair dependence by 4 years in secondary progressive multiple sclerosis
September 12, 2019Research and Development ECTRIMS 2019, Mayzent, Novartis, multiple sclerosis, pharma
Novartis has taken the opportunity at the 2019 Congress of The European Committee for Treatment and Research in Multiple Sclerosis …
